Kytril

Granisetron, the active ingredient in Kytril, is a selective 5‑HT3 receptor antagonist presented as a tablet for oral use. It is indicated for the prevention of chemotherapy‑induced nausea and vomiting and for postoperative nausea and vomiting in adult patients.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution aligned to EU market standards. The company ensures product quality through rigorous quality‑assurance processes and provides regulatory support for importers.

Kytril, a 5‑HT3 receptor antagonist, is used to control nausea and vomiting associated with chemotherapy and surgery. - Chemotherapy‑induced nausea and vomiting: prevents and reduces acute and delayed episodes in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Anticipatory nausea and vomiting: helps patients who have experienced prior chemotherapy‑related nausea to avoid future episodes.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Constipation: reduced bowel movements, usually transient. - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Diarrhea: loose stools, generally mild.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm beyond QT changes. - Intestinal obstruction: severe constipation leading to blockage. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents.

Before prescribing Kytril, consider the following precautions: - Cardiac assessment: evaluate patients with known QT prolongation or arrhythmias. - Electrolyte monitoring: correct hypokalemia, hypomagnesemia, or hypocalcemia that may increase cardiac risk. - Hepatic impairment: use with caution in patients with liver dysfunction. - Concomitant QT‑prolonging drugs: avoid or monitor closely when used together. - Renal function: adjust use in severe renal impairment if required. - Store below 25°C: keep in the original pack, protect from moisture.

Kytril may interact with other medicines as follows: Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, amiodarone): increased risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise granisetron plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. Moderate Interactions (Monitor Closely): - Other 5‑HT3 antagonists (e.g., ondansetron): additive antiemetic effect and potential for constipation. - Opioids: enhanced sedation and respiratory depression. - Anticholinergic agents: increased risk of severe constipation. - Antidepressants with serotonergic activity: monitor for signs of serotonin syndrome.